Expression and biological characterization of an anti-CD20 biosimilar candidate antibody: A case study

mAbs

Volumn 4, Issue 4, 2012, Pages 488-496

  Dorvignit, Denise ^a   Palacios, Julio L ^a   Merino, Maylin ^b   Hernández, Tays ^a   Sosa, Katya ^a   Casacó, Angel ^a   López Requena, Alejandro ^a   De Acosta, Cristina Mateo ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b Center of Advanced Studies   (Cuba)

Author keywords

Antibody dependent mediated cell cytotoxicity; Apoptosis; Biosimilar antibody; Cytotoxicity dependent complement; Rituximab

Indexed keywords

CD20 ANTIBODY; RITUXIMAB;

ANIMAL CELL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ANTIBODY PRODUCTION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CONTROLLED STUDY; FED BATCH CULTURE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; APOPTOSIS; B-LYMPHOCYTES; CELL LINE, TUMOR; CELLS, CULTURED; CHO CELLS; COMPLEMENT SYSTEM PROTEINS; CRICETINAE; CRICETULUS; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; HUMANS; K562 CELLS; LEUKOCYTES, MONONUCLEAR; MACACA FASCICULARIS; PROTEIN ENGINEERING;

EID: 84863458013     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.20761     Document Type: Article

References (38)

1. Hultin LE, Hausner MA, Hultin PM, Giorgi JV. CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 1993; 14:196-204; PMID:7679964; http://dx.doi.org/10.1002/cyto.990140212.
2. Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003; 62:55-9; PMID:14532151; http://dx.doi.org/10.1136/ard.62.suppl-2.ii55.
3. Looney RJ, Anolik J, Sanz I. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 2004; 13:381-90; PMID:15230297; http://dx.doi.org/10.1191/0961203304lu1031oa.
4. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-45; PMID:7506951.
5. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006; 12:4027-35; PMID:16818702; http://dx.doi.org/10.1158/1078-0432.CCR-06- 0066.
6. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171:1581-7; PMID:12874252.
7. Bellosillo B, Villamor N, López-Guillermo A, MarcéS, Esteve J, Campo E, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001; 98:2771-7; PMID:11675350; http://dx.doi.org/10.1182/blood. V98.9.2771.
8. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003; 101:949-54; PMID:12393572; http://dx.doi.org/10.1182/blood-2002-02-0469.
9. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704.
10. Byrd JC, Kitada S, Flinn IW, Aron JL, Pearson M, Lucas D, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002; 99:1038-43; PMID:11807010; http://dx.doi.org/10.1182/ blood.V99.3.1038.
11. Vugmeyster Y, Howell K, Bakshl A, Flores C, Canova-Davis E. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix. Cytometry A 2003; 52:101-9; PMID:12655653; http://dx.doi.org/10.1002/cyto.a.10030.
12. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol 2008; 19:411-9; PMID:17872902; http://dx.doi.org/10.1093/annonc/mdm345.
13. Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, et al. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem 2009; 392:145-54; PMID:19497295; http://dx.doi.org/10.1016/j.ab.2009.05.043.
14. Coloma MJ, Hastings A, Wims LA, Morrison SL. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 1992; 152:89-104; PMID:1640112; http://dx.doi.org/10.1016/0022-1759(92)90092-8.
15. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84:1415-20; PMID:8068938.
16. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91:1644-52; PMID:9473230.
17. Hofmeister JK, Cooney D, Coggeshall KM. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol Dis 2000; 26:133-43; PMID:10753604; http://dx.doi.org/10.1006/bcmd.2000.0287.
18. Bae SW, Hong HJ, Lee GM. Stability of transfectomas producing chimeric antibody against the pre-S2 surface antigen of hepatitis B virus during a long-term culture. Biotechnol Bioeng 1995; 47:243-51; PMID:18623398; http://dx.doi.org/10.1002/bit.260470216.
19. Sleiman RJGP, Gray PP, McCall MN, Codamo J, Sunstrom NA. Accelerated cell line development using two-color fluorescence activated cell sorting to select highly expressing antibody-producing clones. Biotechnol Bioeng 2008; 99:578-87; PMID:17680677; http://dx.doi.org/10.1002/bit.21612.
20. Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, et al. Binding to CD20 by anti- B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines. Cancer Immunol Immunother 2002; 51:15-24; PMID:11845256; http://dx.doi. org/10.1007/s00262-001-0247-1.
21. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000; 95:3900-8; PMID:10845926.
22. Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007; 44:3823-37; PMID:17768100; http://dx.doi.org/10.1016/j.molimm.2007.06.151.
23. Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471-8; PMID:18606225; http://dx.doi.org/10.1016/j.coi.2008.06.007.
24. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Methods 1983; 64:313-20; PMID:6199426; http://dx.doi.org/10.1016/0022-1759(83)90438-6.
25. Shi YX, Zhang XS, Xia JC, Li YQ, Xu RH, Han WJ, et al. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells]. Ai Zheng 2007; 26:837-42; PMID:17697543.
26. Watanabe M, Wallace PK, Keler T, Deo YM, Akewanlop C, Hayes DF. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210. Breast Cancer Res Treat 1999; 53:199-207; PMID:10369066; http://dx.doi.org/10.1023/A:1006145507567.
27. van der Kolk LE, Evers LM, Omene C, Lens SM, Lederman S, van Lier RA, et al. CD20-induced B cell death can bypass mitochondria and caspase activation. Leukemia 2002; 16:1735-44; PMID:12200688; http://dx.doi.org/10.1038/sj.leu. 2402559.
28. Daniels I, Abulayha AM, Thomson BJ, Haynes AP. Caspase-independent killing of Burkitt lymphoma cell lines by rituximab. Apoptosis 2006; 11:1013-23; PMID:16544097; http://dx.doi.org/10.1007/s10495-006-6314-5.
29. Pedersen IM, Buhl AM, Klausen P, Geisler CH, Jurlander J. The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood 2002; 99:1314-9; PMID:11830481; http://dx.doi.org/10.1182/ blood.V99.4.1314.
30. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem 1994; 269:30761-4; PMID:7983002.
31. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-kappaB signaling pathway in non-Hodgkin's lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res 2005; 65:264-76; PMID:15665303.
32. Janas E, Priest R, Wilde JI, White JH, Malhotra R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol 2005; 139:439-46; PMID:15730389; http://dx.doi.org/10.1111/j.1365-2249.2005.02720.x.
33. Kennedy AD, Solga MD, Schuman TA, Chi AW, Lindorfer MA, Sutherland WM, et al. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. Blood 2003; 101:1071-9; PMID:12393727; http://dx.doi.org/10.1182/blood-2002-03-0876.
34. Roque-Navarro L, Mateo C, Lombardero J, Mustelier G, Fernández A, Sosa K, et al. Humanization of predicted T-cell epitopes reduces the immunogenicity of chimeric antibodies: new evidence supporting a simple method. Hybrid Hybridomics 2003; 22:245-57; PMID:14511570; http://dx.doi.org/10.1089/ 153685903322328974.
35. López-Requena A, Mateo de Acosta C, Pérez A, Valle A, Lombardero J, Sosa K, et al. Chimeric anti- N-glycolyl-ganglioside and its anti-idiotypic MAbs: immunodominance of their variable regions. Hybrid Hybridomics 2003; 22:235-43; PMID:14511569; http://dx.doi.org/10.1089/ 153685903322328965.
36. Coligan JEKA, Marguleis DH, Shevach EM, Strober W. Purification and fragmentation of antibodies. Current Protocols in Immunology, Wiley 1995; 1:285.
37. López-Requena A, De Acosta CM, Moreno E, González M, Puchades Y, Talavera A, et al. Gangliosides, Ab1 and Ab2 antibodies I. Towards a molecular dissection of an idiotype-anti-idiotype system. Mol Immunol 2007; 44:423-33; PMID:16581129.
38. Bayer EA, Wilchek M. The use of the avidin-biotin complex as a tool in molecular biology. Methods Biochem Anal 1980; 26:1-45; PMID:7392958; http://dx.doi.org/10.1002/9780470110461.ch1.